Related Experiment Video
Updated: May 8, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
1Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. hakan.mellstedt@karolinska.se
Summary
Biosimilars, copies of complex biopharmaceuticals like anti-cancer monoclonal antibodies, face unique regulatory pathways. Careful risk-benefit evaluation is crucial due to potential undetected differences and extrapolated indications.
Area of Science:
- Biotechnology
- Oncology
- Pharmacology
Background:
- Biopharmaceuticals, complex protein drugs from living organisms, represent advances in cancer treatment.
- Upon patent expiry, similar copies called biosimilars are developed, requiring distinct regulatory approval processes.
- Unlike identical chemical generics, biosimilars are only similar to innovator biopharmaceuticals.
Purpose of the Study:
- To outline the regulatory differences between biosimilars and chemical generics.
- To highlight the challenges in approving anti-neoplastic biosimilar monoclonal antibodies.
- To emphasize the need for careful risk-benefit assessment of biosimilars in oncology.
Main Methods:
- Comparative analysis of regulatory pathways for biosimilars and chemical generics.
- Review of the comparability exercise requirements for biosimilar approval.
- Examination of post-approval data and indication extrapolation for biosimilars.
Main Results:
- Biosimilars require extensive comparability studies, not identical synthesis.
- Potential undetected differences between innovator and biosimilar antibodies necessitate further clinical evaluation.
- Indications for biosimilars may be extrapolated, with limited initial data.
Conclusions:
- The approval of biosimilar anti-neoplastic monoclonal antibodies balances price reduction with potential risks.
- A thorough risk-benefit evaluation is essential, considering the curative intent of cancer therapies.
- Modest price reductions and the proportion of biopharmaceutical costs in overall healthcare spending warrant careful consideration.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...